ProfessorThe First Affiliated Hospital of University of Science and Technology of China,Anhui, P.R. ChinaHefei, Anhui, China (People's Republic)
PB0265 - Reduced doses of emicizumab achieve good efficacy: results from a national-wide multicenter real-world study in China
Sunday, June 23, 202413:45 – 14:45 ICT
OC 21.5 - An Open-label,Dose-Escalation,Multicenter Phase I Study to Evaluate the Safety,Immunogenicity,and Pharmacokinetics/pharmacodynamics（PK/PD）of Single Dose SS109 in Hemophilia A/B patients with Inhibitor
Sunday, June 23, 202415:45 – 16:00 ICT
